Press releases
- Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Sarepta Therapeutics to Present at Upcoming Investor Conferences
- Sarepta Therapeutics Announces Call for Applications for the 7th Annual Route 79, The Duchenne Scholarship Program
- Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Recent Corporate Developments
- Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2023 Financial Results
- Sarepta Therapeutics Announces U.S. FDA Acceptance of an Efficacy Supplement to Expand the ELEVIDYS Indication
- Sarepta Therapeutics Announces Positive Data from Part B of MOMENTUM, a Phase 2 Study of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51
More ▼
Key statistics
As of last trade Sarepta Therapeutics Inc (AB3A:MUN) traded at 110.10, -23.67% below its 52-week high of 144.25, set on May 16, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 110.10 |
---|---|
High | 110.10 |
Low | 110.10 |
Bid | 110.15 |
Offer | 111.20 |
Previous close | 110.05 |
Average volume | 2.22 |
---|---|
Shares outstanding | 93.86m |
Free float | 89.37m |
P/E (TTM) | -- |
Market cap | 11.06bn USD |
EPS (TTM) | -6.15 USD |
Data delayed at least 15 minutes, as of Apr 18 2024 07:00 BST.
More ▼